<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04224896</url>
  </required_header>
  <id_info>
    <org_study_id>SFED</org_study_id>
    <nct_id>NCT04224896</nct_id>
  </id_info>
  <brief_title>Narrow-Band Imaging (NBI) Versus Lugol Chromoendoscopy in the Detection of Oesophagus Squamous Cell Carcinoma in High Risk Population</brief_title>
  <official_title>Narrow-Band Imaging (NBI) Versus Lugol Chromoendoscopy in the Detection of Oesophagus Squamous Cell Carcinoma in High Risk Population: a Randomised Controlled Multicentre Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Edouard Herriot</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Edouard Herriot</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Narrow-Band Imaging (NBI) is as sensitive as Lugol chromoendoscopy to detect oesophageal
      squamous cell carcinoma (SCC) and appears more specific than Lugol chromoendoscopy in expert
      centres but its specificity in current practice is not known. This study aimed to prove the
      superiority of NBI specificity over Lugol chromoendoscopy to detect oesophageal SCC and
      high-grade dysplasia (HGD) in current practice (including tertiary care centres, local
      hospitals and private clinics).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2011</start_date>
  <completion_date type="Actual">December 31, 2015</completion_date>
  <primary_completion_date type="Actual">March 1, 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SPECIFICITY OF THE TWO DIAGNOSTIC STRATEGIES</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">335</enrollment>
  <condition>FRENCH STUDY</condition>
  <arm_group>
    <arm_group_label>NBI PATIENT</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>LUGOL PATIENT</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>UPPER ENDOSCOPY</intervention_name>
    <description>UPPER ENDOSCOPY</description>
    <arm_group_label>LUGOL PATIENT</arm_group_label>
    <arm_group_label>NBI PATIENT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HIGH RISK OF OESOPHAGEAL SQUAMOUS CELL CARCINOMA
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients had a history or current SCC

        Exclusion Criteria:

          -  NONE
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Edouard Herriot</investigator_affiliation>
    <investigator_full_name>Jean Christophe Saurin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

